These studies identified mutation and phosphorylation as mechanisms by which ER+ HER2 non-amplified (henceforth referred to as ER+ HER2−) breast cancer cells could activate HER2 signaling to resist endocrine treatment4,7. Here, ERBB2 is linked to breast carcinoma.